GlassScriptPhysician profile
William P Gianakopoulos
NPI 1841239142
$4,357.08
in general payments reported to CMS, 2019-2025
37 companies · $564 in 2025
The $564 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $385 · 2021: $504 · 2022: $930 · 2023: $746 · 2024: $647 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,833 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,832.74 |
| Education | $124.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $424.69 | 2019-2025 | Erleada, Akeega, Balversa |
| Bayer Healthcare Pharmaceuticals INC. | $374.73 | 2019-2024 | |
| Antares Pharma, INC. | $356.15 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Dendreon Pharmaceuticals LLC | $326.16 | 2019-2024 | Provenge |
| Progenics Pharmaceuticals, INC. | $317.85 | 2021-2025 | |
| Astellas Pharma US INC | $302.60 | 2019-2024 | Myrbetriq, Xtandi |
| Sumitomo Pharma America, INC. | $284.88 | 2023-2025 | Orgovyx, Gemtesa |
| Astrazeneca Pharmaceuticals LP | $275.75 | 2020-2022 | |
| Pfizer INC. | $258.31 | 2019-2025 | |
| Myovant Sciences INC. | $183.46 | 2021-2022 | |
| Boston Scientific Corporation | $178.68 | 2022 | |
| Teleflex LLC | $147.34 | 2021 | |
| Merck Sharp & Dohme LLC | $139.97 | 2024-2025 | Keytruda |
| Urogen Pharma, INC. | $89.68 | 2021-2025 | Jelmyto |
| Endo Pharmaceuticals INC. | $87.31 | 2019-2023 | Aveed, Xiaflex |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $64.94 | 2023 | |
| Abbvie INC. | $61.63 | 2024-2025 | |
| Coloplast Corp | $60.00 | 2020-2022 | |
| Endo USA, INC. | $54.76 | 2024-2025 | Xiaflex, Aveed |
| Urovant Sciences INC | $36.12 | 2021-2022 | |
| 180 Medical, INC. | $32.53 | 2019 | |
| Genzyme Corporation | $25.60 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.31 | 2023 | |
| Myriad Genetic Laboratories, INC. | $23.76 | 2025 | Prolaris |
| Azurity Pharmaceuticals, INC. | $23.69 | 2025 | Azmiro |
| Verity Pharmaceuticals INC. | $22.26 | 2025 | Tlando |
| Blue Earth Diagnostics | $20.27 | 2020 | |
| Tolmar, INC. | $20.25 | 2023 | |
| Olympus America INC. | $19.94 | 2023 | Itind System |
| Vertex Pharmaceuticals Incorporated | $19.84 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $18.39 | 2022 | |
| Foundation Medicine, INC. | $17.65 | 2023 | |
| Amgen INC. | $17.55 | 2023 | Xgeva |
| Sun Pharmaceutical Industries INC. | $17.25 | 2019 | |
| Telix Pharmaceuticals | $15.12 | 2022 | |
| Srs Medical Systems, INC. | $13.66 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$990.50 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Gianakopoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.